These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26206991)

  • 21. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
    Stingl J; Viviani R
    J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antidepressant pharmacokinetics during pregnancy].
    Maslovskiĭ SIu
    Eksp Klin Farmakol; 2013; 76(1):14-20. PubMed ID: 23461010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
    Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
    Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of CYP allelic variation on antidepressant metabolism: a review.
    Black JL; O'Kane DJ; Mrazek DA
    Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):21-31. PubMed ID: 17269892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics.
    Cohen LJ; De Vane CL
    Ann Pharmacother; 1996 Dec; 30(12):1471-80. PubMed ID: 8968460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.
    Saiz-Rodríguez M; Belmonte C; Derqui-Fernández N; Cabaleiro T; Román M; Ochoa D; Talegón M; Ovejero-Benito MC; Abad-Santos F
    Pharmacogenomics; 2017 Nov; 18(16):1491-1502. PubMed ID: 29061081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.
    Jann MW; Cohen LJ
    Drug Metabol Drug Interact; 2000; 16(1):39-67. PubMed ID: 10820582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.
    Breitenstein B; Scheuer S; Brückl TM; Meyer J; Ising M; Uhr M; Holsboer F
    J Psychiatr Res; 2016 Feb; 73():86-95. PubMed ID: 26704739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review.
    Bigos KL; Pollock BG; Stankevich BA; Bies RR
    Gend Med; 2009 Dec; 6(4):522-43. PubMed ID: 20114004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of pharmacogenetics in the treatment of depression and anxiety disorders.
    Schosser A; Kasper S
    Int Clin Psychopharmacol; 2009 Nov; 24(6):277-88. PubMed ID: 19738481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.
    Grasmäder K; Verwohlt PL; Rietschel M; Dragicevic A; Müller M; Hiemke C; Freymann N; Zobel A; Maier W; Rao ML
    Eur J Clin Pharmacol; 2004 Jul; 60(5):329-36. PubMed ID: 15168101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic considerations for late life depression therapy.
    Pitychoutis PM; Kokras N; Sanoudou D; Dalla C; Papadopoulou-Daifoti Z
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):989-99. PubMed ID: 23641676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depression and Pharmacogenetics.
    Ampong DN
    Arch Psychiatr Nurs; 2018 Feb; 32(1):71-74. PubMed ID: 29413077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.
    Fabbri C; Serretti A
    Curr Psychiatry Rep; 2015 Jul; 17(7):50. PubMed ID: 25980509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of antidepressant response.
    Keers R; Aitchison KJ
    Expert Rev Neurother; 2011 Jan; 11(1):101-25. PubMed ID: 21158559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics in the treatment of depression: pharmacodynamic studies.
    Serretti A; Artioli P; Quartesan R
    Pharmacogenet Genomics; 2005 Feb; 15(2):61-7. PubMed ID: 15861029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.
    Hermann R; von Richter O
    Planta Med; 2012 Sep; 78(13):1458-77. PubMed ID: 22855269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.